Semaglutide

AIMS: The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without ty…

CONTEXT: Whether continuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) or switching to oral semaglutide is more beneficial for β-cell function is unclear. OBJECTIVE: To assess the efficacy of switching from DPP-4is to oral semaglutide for β-cel…

BACKGROUND: Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, surgery, and steroid-free remission. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstra…

INTRODUCTION AND OBJECTIVES: Disruptions in one-carbon metabolism (OCM) have been linked to cardiometabolic diseases. We evaluated alterations in OCM metabolites and enzymes and the impact of semaglutide in MASLD. MATERIALS AND METHODS: Using targete…

INTRODUCTION: Early treatment of obesity is essential and requires proactive engagement from healthcare providers. A 2022 survey among the members of the Italian Association of Clinical Endocrinologists (AME) revealed that they often did not address…

BACKGROUND: Metabolic-associated fatty liver disease (MAFLD) is a leading cause of chronic liver disease and is closely linked to type 2 diabetes mellitus (T2DM). The pathogenesis of MAFLD involves complex metabolic imbalances, including impaired fat…

BACKGROUND & AIMS: Semaglutide has demonstrated efficacy in both glycemic control and weight loss. This systematic review and meta-analysis aimed to assess the efficacy and safety of the combined use of semaglutide and basal insulin in individuals di…

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely utilized for managing diabetes and obesity due to their efficacy in improving glycemic control and promoting weight loss. However, their gastrointestinal effects, such as slowed motility…

INTRODUCTION: The glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved as an oral formulation for the treatment of type 2 diabetes. This study aimed to confirm bioequivalence between a new, second-generation (2G) oral semaglutide formulat…

BACKGROUND: The American Diabetes Association recommends the use of glucagon-like-peptide-1 receptor agonists (GLP1-RAs) (e.g., Ozempic) for patients with atherosclerotic cardiovascular disease, including peripheral artery disease. We hypothesized in…

This article highlights some important nephrology studies published in 2024 that may be relevant for nonnephrologist physicians. Four studies examined progression of chronic kidney disease (CKD), cardiovascular events, and nephrolithiasis with respec…

OBJECTIVE: The purpose of this study was to evaluate insulin dose requirements after the addition of the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist tirzepatide compared with the GLP-1 receptor a…

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Antidiabetic agents, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agoni…

Discourse around the usage of weight-loss drugs (semaglutide, GLP-1 agonists, Ozempic, Wegovy) center around how people are precluded from access, a phenomenon understood as stratified biomedicalization. However, this research project finds people re…

INTRODUCTION: This study evaluated the long-term effectiveness of once-weekly subcutaneous semaglutide versus alternative treatment in adults with type 2 diabetes (T2D) in routine clinical practice. RESEARCH DESIGN AND METHODS: The SEmaglutide PRAgma…

AIM: To compare the cardiovascular outcomes of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among adults with type 2 diabetes mellitus (T2D) at moderate cardiovascular risk. METHODS: We emulated a target trial using claims data of adults with…